OnCall

Treating with TIBSOVO: A targeted therapeutic option for patients with R/R mIDH1 AML

August 03, 2021 AmerisourceBergen Episode 1
OnCall
Treating with TIBSOVO: A targeted therapeutic option for patients with R/R mIDH1 AML
Show Notes

Listen to a discussion between Jonathan Abbas, MD, and Mark Levis, MD, PhD.

Please listen to additional safety information for TIBSOVO® (ivosidenib tablets) at the end of this presentation. Please visit TibsovoPro.com to review the Full Prescribing Information, including BOXED WARNING.